184 related articles for article (PubMed ID: 25817799)
1. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
Br J Haematol; 2015 Jun; 169(5):683-8. PubMed ID: 25817799
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
3. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
4. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.
Rebora P; Czene K; Antolini L; Gambacorti Passerini C; Reilly M; Valsecchi MG
Am J Epidemiol; 2010 Nov; 172(9):1028-33. PubMed ID: 20861143
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
[TBL] [Abstract][Full Text] [Related]
6. Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.
Gunnarsson N; Höglund M; Stenke L; Wållberg-Jonsson S; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Wadenvik H; Richter J; Själander A
Leukemia; 2016 Jul; 30(7):1562-7. PubMed ID: 27080811
[TBL] [Abstract][Full Text] [Related]
7. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia.
Voglova J; Muzik J; Faber E; Zackova D; Klamova H; Steinerova K; Michalovicova Z; Demitrovicova L; Cmunt E; Novakova L; Tothova E; Belohlavkova P; Mayer J; Indrak K
Neoplasma; 2011; 58(3):256-62. PubMed ID: 21395367
[TBL] [Abstract][Full Text] [Related]
8. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
Miranda MB; Lauseker M; Kraus MP; Proetel U; Hanfstein B; Fabarius A; Baerlocher GM; Heim D; Hossfeld DK; Kolb HJ; Krause SW; Nerl C; Brümmendorf TH; Verbeek W; Fauser AA; Prümmer O; Neben K; Hess U; Mahlberg R; Plöger C; Flasshove M; Rendenbach B; Hofmann WK; Müller MC; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R; Saußele S
Leukemia; 2016 Jun; 30(6):1255-62. PubMed ID: 26859076
[TBL] [Abstract][Full Text] [Related]
9. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; O'Brien S; Ravandi F; Konopleva M; Borthakur G; Garcia-Manero G; Wierda WG; Daver N; Ferrajoli A; Takahashi K; Jain P; Rios MB; Pierce SA; Jabbour EJ; Cortes JE
Int J Hematol; 2019 May; 109(5):545-552. PubMed ID: 30830579
[TBL] [Abstract][Full Text] [Related]
10. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
Söderlund S; Dahlén T; Sandin F; Olsson-Strömberg U; Creignou M; Dreimane A; Lübking A; Markevärn B; Själander A; Wadenvik H; Stenke L; Richter J; Höglund M
Eur J Haematol; 2017 Jan; 98(1):57-66. PubMed ID: 27428357
[TBL] [Abstract][Full Text] [Related]
11. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.
Gugliotta G; Castagnetti F; Fogli M; Cavo M; Baccarani M; Rosti G
Expert Rev Hematol; 2013 Oct; 6(5):563-74. PubMed ID: 24083631
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of chronic myeloid leukaemia: an update.
Höglund M; Sandin F; Simonsson B
Ann Hematol; 2015 Apr; 94 Suppl 2():S241-7. PubMed ID: 25814090
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
Koller PB; Kantarjian HM; Nogueras-Gonzalez GM; Jabbour E; Verstovsek S; Borthakur G; Estrov Z; Wierda WG; Garcia-Manero G; Ferrajoli A; Ravandi F; O'Brien SM; Cortes JE
Cancer; 2017 Feb; 123(4):609-616. PubMed ID: 27763690
[TBL] [Abstract][Full Text] [Related]
16. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
Gunnarsson N; Sandin F; Höglund M; Stenke L; Björkholm M; Lambe M; Olsson-Strömberg U; Richter J; Själander A
Eur J Haematol; 2016 Oct; 97(4):387-92. PubMed ID: 26833713
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
18. Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Flygt H; Sandin F; Dahlén T; Dremaine A; Lübking A; Markevärn B; Myhr-Eriksson K; Olsson K; Olsson-Strömberg U; Själander A; Söderlund S; Wennström L; Wadenvik H; Stenke L; Höglund M; Richter J
Br J Haematol; 2021 Jun; 193(5):915-921. PubMed ID: 33782950
[TBL] [Abstract][Full Text] [Related]
19. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Verma D; Kantarjian H; Strom SS; Rios MB; Jabbour E; Quintas-Cardama A; Verstovsek S; Ravandi F; O'Brien S; Cortes J
Blood; 2011 Oct; 118(16):4353-8. PubMed ID: 21846902
[TBL] [Abstract][Full Text] [Related]
20. Managing pregnancy in chronic myeloid leukaemia.
Palani R; Milojkovic D; Apperley JF
Ann Hematol; 2015 Apr; 94 Suppl 2():S167-76. PubMed ID: 25814083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
